Holdings
Select Pharmaceuticals Portfolio
As of May 31, 2026, Select Pharmaceuticals Portfolio reported 38 positions worth US$1.39B. Largest: Eli Lilly and Company, GSK plc and Viatris Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly and Company | 391K | US$432M | +28,000 | May 31, 2026 |
| GSK plc | 4.82M | US$123M | −374K | May 31, 2026 |
| Viatris Inc. | 5.03M | US$81.8M | +3.3M | May 31, 2026 |
| Ucb S.A. | 260K | US$76.4M | +5,600 | May 31, 2026 |
| Merck & Company, Inc. | 599K | US$71.2M | +37,800 | May 31, 2026 |
| Roche Holding Ltd | 162K | US$68.2M | −25,694 | May 31, 2026 |
| AstraZeneca PLC | 341K | US$63.4M | −16,900 | May 31, 2026 |
| Elanco Animal Health Incorporated | 2.61M | US$62.3M | +74,800 | May 31, 2026 |
| Jazz Pharmaceuticals plc | 260K | US$61.4M | +31,900 | May 31, 2026 |
| Gilead Sciences, Inc. | 443K | US$59.5M | −29,700 | May 31, 2026 |